Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.California-based Amgen is planning to build growth by widening the use of its latest approved medicine, denosumab, used to treat osteoporosis and delay fractures from cancer.
Subscribe to our email newsletter
Amgen plans to simultaneously develop three oncology drugs, the most advanced of them being Motesanib, which is being developed in collaboration with the Tokyo-based Takeda Pharmaceutical.
Referring to the two forms of denosumab the company is now marketing, Amgen chairman and CEO Kevin Sharer said after working for 15 years, investing a billion and a half dollars and overcoming many challenges, they brought to market two very important medicines that we are very optimistic about.
Bloomberg.com has quoted Amgen chief medical officer Sean Harper as saying that he feels very good about the fact that they haven’t built an oncology-focused pipeline, it’s a healthy proportion of their pipeline.